Rapport Therapeutics RAPP
NASDAQ RAPP
$26.43 +0.47 (+1.81%)
As of: Nov 11, 2026 · 1:52 PM EST

Rapport Therapeutics (RAPP) Price to Sales (2026)

Updated

Rapport Therapeutics' (RAPP) Price to Sales stood at 99.91 in Q2 2026.

Analysis

Rapport Therapeutics (RAPP) Price to Sales (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Rapport Therapeutics 1.25 Bn 853.38 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 80.79
Jun 30, 2026 99.91
Mar 31, 2026 74.79
API Access

Rapport Therapeutics Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=RAPP&period=max&api_key=YOUR_API_KEY